RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+3.6%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$955M
AUM Growth
+$955M
(+8.5%)
Cap. Flow
+$13.3M
Cap. Flow
% of AUM
1.39%
Top 10 Holdings %
Top 10 Hldgs %
28.16%
Holding
94
New
8
Increased
32
Reduced
32
Closed
4
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$13.5M |
| 2 |
Becton Dickinson
BDX
|
$9.44M |
| 3 |
Biogen
BIIB
|
$9.29M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$8.4M |
| 5 |
Thermo Fisher Scientific
TMO
|
$7.92M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$14.9M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$12.2M |
| 3 |
Cigna
CI
|
$11.6M |
| 4 |
Elevance Health
ELV
|
$9.3M |
| 5 |
Pfizer
PFE
|
$8.84M |
Sector Composition
| 1 | Healthcare | 98.85% |
| 2 | Industrials | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$657B
| $35.1M | 3.68% | 97,000 +7,000 | +8% | +$2.53M |
|
2
UnitedHealth
UNH
$281B
| $30.4M | 3.19% | 54,800 -1,200 | -2% | -$666K |
|
3
Boston Scientific
BSX
$156B
| $30M | 3.14% | 695,000 -30,000 | -4% | -$1.29M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $30M | 3.14% | 96,000 +1,000 | +1% | +$312K |
|
|
5
Thermo Fisher Scientific
TMO
$186B
| $27M | 2.83% | 52,500 +15,400 | +42% | +$7.92M |
|
6
Humana
HUM
$36.5B
| $24.6M | 2.57% | 44,000 +1,000 | +2% | +$558K |
|
|
7
Cigna
CI
$80.3B
| $24.2M | 2.54% | 75,000 -36,000 | -32% | -$11.6M |
|
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $24M | 2.51% | 32,000 +18,000 | +129% | +$13.5M |
|
9
AbbVie
ABBV
$372B
| $21.9M | 2.29% | 149,626 -40,374 | -21% | -$5.91M |
|
|
10
Elevance Health
ELV
$71.8B
| $21.9M | 2.29% | 40,000 -17,000 | -30% | -$9.3M |
|
11
Merck
MRK
$210B
| $21.8M | 2.28% | 215,000 -50,000 | -19% | -$5.06M |
|
|
ABMD
12
DELISTED
Abiomed Inc
ABMD
| $21.7M | 2.27% | 85,900 +12,900 | +18% | +$3.25M |
|
13
Cencora
COR
$56.5B
| $21.4M | 2.24% | 136,000 +11,000 | +9% | +$1.73M |
|
14
CVS Health
CVS
$92.8B
| $21.3M | 2.23% | 225,000 -65,000 | -22% | -$6.16M |
|
15
Gilead Sciences
GILD
$140B
| $21.2M | 2.22% | 270,000 +70,000 | +35% | +$5.49M |
|
16
Medtronic
MDT
$119B
| $21M | 2.2% | 240,000 +90,000 | +60% | +$7.86M |
|
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $20.5M | 2.15% | 237,000 +97,000 | +69% | +$8.4M |
|
|
18
Becton Dickinson
BDX
$55.3B
| $20.1M | 2.1% | 85,000 +40,000 | +89% | +$9.44M |
|
19
McKesson
MCK
$85.4B
| $19.5M | 2.04% | 50,000 -13,000 | -21% | -$5.06M |
|
20
Jazz Pharmaceuticals
JAZZ
$7.75B
| $18.9M | 1.98% | 131,500 -28,500 | -18% | -$4.1M |
|
21
Johnson & Johnson
JNJ
$427B
| $17.4M | 1.82% | 100,000 | – | – |
|
|
22
Pfizer
PFE
$141B
| $16.3M | 1.71% | 350,000 -190,000 | -35% | -$8.84M |
|
23
Danaher
DHR
$147B
| $15.6M | 1.63% | 62,000 +8,000 | +15% | +$2.01M |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $15.5M | 1.63% | 75,000 | – | – |
|
|
AXNX
25
DELISTED
Axonics, Inc. Common Stock
AXNX
| $15.4M | 1.61% | 210,000 -30,000 | -13% | -$2.19M |
|